Adult Dosing

Tinea pedis

• Apply to affected areas Daily for 2 wks

Tinea cruris or tinea corporis

• Apply to affected areas Daily for 1 wk

Note:

• Not for ophthalmic, oral, or intravaginal use

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients >18 years of age

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• N/A

Pregnancy Category:C

Breastfeeding: Safety unknown. Manufacturer advises caution

• DERM: Application site reactions

• Antifungal agent; inhibits ergosterol synthesis resulting in increased cellular permeability causing leakage of cellular contents
• Minimal systemic absorption with topical application
• Metabolism: Unknown; CYP450: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Luzu

US Availability

Luzu

• CRE: 1%

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Dermatologic

Dermatologic Topical Agents

Antifungals